Oct 10, 2016 Cerecor to Present at the 15th Annual BIO Investor Forum in San Francisco on October 18th, 2016
Sep 21, 2016 Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
Sep 12, 2016 Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Sep 6, 2016 Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
Sep 1, 2016 Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
